SL PHARM(002038)2021-10-27 16:00Revenue and Profit - Revenue for Q3 2021 was ¥288,851,487.11, a decrease of 5.38% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2021 was ¥134,398,018.19, an increase of 26.25% year-over-year[6] - Net profit excluding non-recurring gains and losses for the year-to-date was ¥226,054,067.90, reflecting a growth of 51.40% compared to the previous year[6] - The basic earnings per share for Q3 2021 was ¥0.1308, up 26.13% from the same period last year[6] - Net profit for the current period was ¥432,602,879.45, up 43.1% from ¥302,211,357.14 in the previous period[33] - Earnings per share (EPS) for the current period was ¥0.4243, up from ¥0.2952 in the previous period, representing a growth of 43.6%[36] - The total comprehensive income for the current period was ¥428,017,810.54, compared to ¥308,351,409.63 in the previous period, marking a growth of 38.8%[33] Assets and Liabilities - Total assets as of the end of Q3 2021 reached ¥5,730,883,415.47, a growth of 6.23% from the end of the previous year[6] - The total assets of the company reached CNY 5,730,883,415.47, up from CNY 5,394,828,767.77, which is an increase of approximately 6.2%[22] - The total liabilities amounted to CNY 411,230,890.18, slightly up from CNY 410,093,857.05, showing a marginal increase of about 0.3%[26] - The company's equity attributable to shareholders increased to CNY 5,303,227,053.09 from CNY 4,974,606,534.39, reflecting a growth of approximately 6.6%[26] Cash Flow - The company reported a net cash flow from operating activities of ¥281,481,980.56 for the year-to-date, an increase of 47.83% compared to the previous year[6] - The company reported a net cash flow from operating activities of ¥281,481,980.56, compared to ¥190,410,390.49 in the previous period, indicating a growth of 47.9%[37] - Net cash flow from investing activities was -707.48 million in the previous period[40] - The net cash flow from financing activities was -207.38 million in the previous period[40] - The ending balance of cash and cash equivalents was 525.11 million in the previous period[40] - Cash and cash equivalents increased by 724.99 million in the previous period[40] Research and Development - R&D expenses increased by 53.91% year-over-year, indicating a significant investment in new product development[11] - Research and development expenses increased significantly to ¥120,662,330.57, a rise of 54% compared to ¥78,396,100.53 in the previous period[30] Investment Income - Investment income increased by 40.72% year-over-year, primarily due to dividends received and the disposal of certain investments[11] - The company achieved an investment income of ¥13,053,972.82, an increase from ¥11,615,243.86 in the previous period[30] Inventory and Receivables - Accounts receivable decreased to CNY 373,091,029.55 from CNY 445,861,765.60, indicating a decline of approximately 16.3%[22] - The company’s inventory increased to CNY 124,652,378.02 from CNY 112,032,165.08, representing a growth of approximately 11.3%[22] Other Financial Metrics - The weighted average return on net assets was 2.67%, an increase of 0.48% compared to the previous year[6] - Total operating revenue for the current period reached ¥913,380,348.89, an increase of 8.4% compared to ¥842,436,354.01 in the previous period[30] - Total operating costs decreased to ¥678,622,148.26 from ¥687,611,299.47, reflecting a reduction of 1.3%[30] - Sales expenses decreased to ¥351,462,911.58 from ¥410,376,435.37, a reduction of 14.3%[30] - The company reported a financial expense of -¥12,650,089.38, compared to -¥2,452,373.33 in the previous period, indicating a significant increase in financial costs[30] Audit Status - The company did not undergo an audit for the third quarter report[43]